Vanja Wilson, 40, is currently confronting stage four ovarian cancer, a disease often referred to as the “silent killer” due to its aggressive nature and late-stage diagnosis. Her journey, marked by rapid shifts from health to serious illness, highlights ongoing challenges faced by many women with this condition.
Two years ago, Wilson was at the peak of her career as a general manager for a technology platform and led an active lifestyle with her husband Calum, 43, and their two young daughters on the Northern Beaches. However, a routine medical procedure led to a startling diagnosis. During a colonoscopy, doctors identified a large bowel stricture, prompting fears of either bowel or advanced ovarian cancer.
Wilson describes the moment of diagnosis as surreal, explaining that she felt trapped in a nightmare. “I couldn’t understand it. I was healthy and happy. Everything changed,” she said. Following the diagnosis, she underwent a five-hour surgery that involved a radical hysterectomy and bowel resection. This was succeeded by four months of weekly chemotherapy treatments.
After an initial period of remission, during which Wilson took part in fundraising efforts for the Ovarian Cancer Research Foundation and marked her 40th birthday with hope for the future, routine scans revealed a relapse. “We threw everything at it and it still came back,” she said. She then underwent a second major operation and is currently reported to have no evidence of disease.
Wilson’s experience has reshaped her perspective on life. She now emphasizes living fully in the present, valuing time spent with her family. “I hadn’t realised that the life I had, I loved. It’s a good life,” she reflected, adding, “I just want more of it.”
She has also expressed frustration with the current state of ovarian cancer treatment, pointing out that therapeutic options have seen little advancement over decades. “Our knowledge is so poor, and women are being left behind,” Wilson stated, underscoring the urgent need for improved research and treatment strategies for ovarian cancer patients.